Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757799

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757799

Nasal Vaccines

PUBLISHED:
PAGES: 220 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Nasal Vaccines Market to Reach US$665.3 Million by 2030

The global market for Nasal Vaccines estimated at US$439.4 Million in the year 2024, is expected to reach US$665.3 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$190.5 Million by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$119.7 Million While China is Forecast to Grow at 11.5% CAGR

The Nasal Vaccines market in the U.S. is estimated at US$119.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$142.1 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Nasal Vaccines Market - Key Trends & Drivers Summarized

Why Are Nasal Vaccines Gaining Momentum in Immunization Strategies?

Nasal vaccines are increasingly recognized as a transformative advancement in vaccine delivery systems, offering needle-free, mucosal-based immunization that mimics natural infection pathways. Unlike injectable vaccines that stimulate systemic immunity, nasal vaccines target the mucosal surfaces-the primary entry points for many respiratory pathogens-thereby inducing both systemic and local immunity. This dual response not only improves protective efficacy but also reduces viral shedding and transmission, making nasal vaccines especially valuable during infectious disease outbreaks.

Their ease of administration, particularly in pediatric and needle-phobic populations, is reshaping mass vaccination logistics. Nasal sprays do not require trained personnel or syringes, simplifying distribution in low-resource settings. These features are driving increasing global interest, especially for diseases like influenza, COVID-19, and respiratory syncytial virus (RSV), where rapid, large-scale immunization is often critical. The potential for self-administration and the elimination of biohazardous waste associated with needles further underscore the public health value of this platform.

What Scientific Advances Are Enhancing the Efficacy and Stability of Nasal Vaccines?

Significant innovations in formulation science and delivery technology are boosting the development of nasal vaccines. One major advancement is the use of novel adjuvants and mucoadhesive carriers that enhance antigen retention in the nasal cavity, leading to stronger and longer-lasting immune responses. Liposomes, nanoemulsions, and polymer-based delivery systems are being engineered to protect antigens from degradation while promoting uptake by nasal-associated lymphoid tissue (NALT), the immune inductive site for mucosal immunity.

Thermostability is another area of progress, with researchers developing dry powder nasal vaccines that can be stored at ambient temperatures, bypassing the need for cold-chain logistics. This attribute is especially crucial for deployment in remote or underdeveloped regions. Additionally, recombinant protein subunits and viral vectors are being tailored for intranasal use, offering broader antigen expression profiles and multivalent targeting. Collectively, these advancements are making nasal vaccines more robust, versatile, and compatible with a wider range of pathogens.

How Are End-Use Applications and Public Health Strategies Expanding?

The end-use landscape for nasal vaccines is evolving rapidly, with increasing integration into national immunization schedules, school-based vaccine programs, and pandemic preparedness strategies. Pediatric and geriatric populations are emerging as key target groups due to their high susceptibility to respiratory diseases and the challenges they often face with needle-based vaccinations. Moreover, the ability to administer nasal vaccines without the need for intravenous access makes them highly suitable for use during emergencies and outbreaks in field conditions.

In addition to infectious diseases, research is expanding into nasal vaccines for non-communicable applications such as allergies, Alzheimer’s disease, and cancer immunotherapy. The nasal route provides direct access to the central nervous system via the olfactory bulb, making it an attractive portal for neurological and systemic immune modulation. Government and private-sector collaborations are increasingly exploring nasal immunization not only as a medical solution but as a strategic tool for boosting vaccine acceptance, reducing healthcare system burden, and accelerating outbreak response.

What Factors Are Driving Growth in the Nasal Vaccines Market?

The growth in the nasal vaccines market is driven by several factors tied to advancements in delivery platforms, expansion in target disease profiles, and systemic shifts in immunization infrastructure. One of the primary drivers is the rising demand for needle-free vaccine options that improve patient compliance, particularly among children, the elderly, and needle-averse individuals. This demand is further amplified in mass immunization settings where ease of administration and minimal training requirements reduce logistical complexity.

End-use diversification across public health, travel medicine, pediatric care, and emergency outbreak response is expanding the commercial viability of nasal vaccines. The increased incidence of respiratory illnesses and global preparedness efforts against pandemic threats are driving demand for rapid, scalable, and non-invasive vaccine delivery solutions. Additionally, supportive regulatory pathways and funding initiatives focused on next-generation vaccine platforms are catalyzing R&D investments and accelerating clinical trials.

Technological improvements in formulation stability, cold-chain independence, and multi-antigenic capability are also enhancing the value proposition of nasal vaccines. These attributes are making them particularly attractive for low-resource settings and global vaccination initiatives where traditional injectable vaccines face logistical challenges. As stakeholders across healthcare, biotechnology, and global health policy align around the benefits of mucosal immunization, the nasal vaccines market is poised for robust growth and significant public health impact.

SCOPE OF STUDY:

The report analyzes the Nasal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines, Other Vaccine Types); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Altimmune, Inc.
  • AstraZeneca
  • Bharat Biotech
  • BioDiem Ltd
  • BioNTech SE
  • BlueWillow Biologics
  • Changchun BCHT Biotechnology Co.
  • Codagenix Inc.
  • CyanVac LLC
  • FluGen Inc.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • Intravacc
  • Meissa Vaccines Inc.
  • Ocugen, Inc.
  • Pfizer Inc.
  • Razi Vaccine and Serum Research Institute
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Vaxart, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35409

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nasal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Mucosal Immunity Drives Research and Adoption of Intranasal Vaccine Platforms
    • OEM Development of Needle-Free Delivery Systems Supports Vaccine Acceptance in Pediatric and Geriatric Populations
    • Growth in Respiratory Disease Prevalence, Including COVID-19 and Influenza, Strengthens Use of Nasal Vaccines
    • Push for Self-Administered Vaccine Formats Enhances Market for Nasal Spray Formulations
    • Increasing Demand for Cold Chain-Free and Room Temperature-Stable Vaccines Promotes Innovation in Nasal Delivery
    • OEM Focus on Adjuvant Optimization and Mucoadhesive Formulations Improves Efficacy of Nasal Vaccines
    • Expansion of Nasal Vaccine Clinical Trials Across Infectious Diseases and Allergies Broadens Market Pipeline
    • Rising Government and NGO Investment in Pandemic Preparedness Supports Nasal Vaccine Infrastructure
    • Integration of Nasal Delivery With mRNA and Recombinant Platforms Fuels Next-Gen Vaccine Development
    • Global Vaccination Campaigns in Low-Income Regions Drive Demand for Easy-to-Use, Non-Invasive Formats
    • Push for Mass Immunization Tools That Reduce Needle Waste Supports Nasal Route Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nasal Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • JAPAN
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CHINA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • EUROPE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • FRANCE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • GERMANY
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SPAIN
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Spain 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Russia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AUSTRALIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Australia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • INDIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 80: India Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 82: India Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: India 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: South Korea 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • LATIN AMERICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Argentina 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • BRAZIL
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Brazil 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MEXICO
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Mexico 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MIDDLE EAST
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • IRAN
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Iran 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ISRAEL
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Israel 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UAE 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AFRICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Africa 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!